{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:20:42Z","timestamp":1792603242635,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["DK132408"],"award-info":[{"award-number":["DK132408"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Predicting infliximab pharmacokinetics (PK) is essential for optimizing individualized dosing in pediatric patients with Crohn disease (CD). Machine learning (ML) has emerged as a tool for predicting drug exposure; however, its development typically requires large datasets. This study aimed to develop an ML model for infliximab PK prediction by leveraging population PK model\u2013based synthetic and real-world data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>An initial ML model was trained using the XGBoost algorithm with synthetic infliximab concentration data (n = 560,000) generated from an established pediatric PK model. The prediction errors were assessed using real-world data, including 292 plasma concentrations from 93 pediatric and young adult patients with CD. A second XGBoost model, incorporating clinical features, was used to correct these errors. The performance of the model was evaluated using the root mean square error (RMSE) and mean prediction error (MPE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The first ML model yielded RMSE and MPE values of 6.44 and 1.84 mcg\/mL, respectively. The features of the second XGBoost model included the predicted infliximab concentrations, cumulative dose, and dosing interval duration. A 5-fold cross-validation demonstrated improved performance of the ensemble model (RMSE = 4.30 \u00b1 1.09 mcg\/mL, MPE = 0.21 \u00b1 0.39 mcg\/mL) compared with the initial model and was comparable with the Bayesian approach (RMSE = 4.81 mcg\/mL, MPE = \u22120.67 mcg\/mL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study demonstrated the feasibility of combining synthetic and real-world data to develop an ML-based approach for infliximab PK prediction, potentially enhancing precision dosing in pediatric CD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001348","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T12:36:42Z","timestamp":1748954202000},"page":"98-104","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Machine Learning Modeling for Predicting Infliximab Pharmacokinetics in Pediatric and Young Adult Patients With Crohn Disease: Leveraging Ensemble Modeling With Synthetic and Real-World Data"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0820-1208","authenticated-orcid":false,"given":"Kei","family":"Irie","sequence":"first","affiliation":[{"name":"Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Minar","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio;"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Reifenberg","sequence":"additional","affiliation":[{"name":"University of Cincinnati School of Medicine, Cincinnati, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M.","family":"Boyle","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, Columbus, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Noe","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Wisconsin, Milwaukee, Wisconsin; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Hyams","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Connecticut Children's Medical Center, Hartford, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio;"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"R1-20260108","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"R2-20260108","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","article-title":"The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update","volume":"15","author":"van Rheenen","year":"2020","journal-title":"J Crohn's Colitis"},{"key":"R3-20260108","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/FTD.0000000000001204","article-title":"Best practice for therapeutic drug monitoring of infliximab: position statement from the international association of therapeutic drug monitoring and clinical toxicology","volume":"46","author":"Alsoud","year":"2024","journal-title":"Ther Drug Monit."},{"key":"R4-20260108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11894-023-00895-4","article-title":"Precision dosing of anti-TNF therapy in pediatric inflammatory bowel disease","volume":"25","author":"Samuels","year":"2023","journal-title":"Curr Gastroenterol Rep."},{"key":"R5-20260108","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12909-023-04698-z","article-title":"Revolutionizing healthcare: the role of artificial intelligence in clinical practice","volume":"23","author":"Alowais","year":"2023","journal-title":"BMC Med Educ."},{"key":"R6-20260108","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/cpt.3049","article-title":"Machine learning: a new approach for dose individualization","volume":"115","author":"Li","year":"2024","journal-title":"Clin Pharmacol Ther."},{"key":"R7-20260108","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/cpt.2216","article-title":"Mycophenolic acid exposure prediction using machine learning","volume":"110","author":"Woillard","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"R8-20260108","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cpt.2123","article-title":"Tacrolimus exposure prediction using machine learning","volume":"110","author":"Woillard","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"R9-20260108","doi-asserted-by":"crossref","first-page":"105331","DOI":"10.1016\/j.isci.2022.105331","article-title":"Synthetic data as an enabler for machine learning applications in medicine","volume":"25","author":"Rajotte","year":"2022","journal-title":"iScience"},{"key":"R10-20260108","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41551-021-00751-8","article-title":"Synthetic data in machine learning for medicine and healthcare","volume":"5","author":"Chen","year":"2021","journal-title":"Nat Biomed Eng."},{"key":"R11-20260108","doi-asserted-by":"crossref","first-page":"105578","DOI":"10.1016\/j.phrs.2021.105578","article-title":"Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: the example of tacrolimus","volume":"167","author":"Woillard","year":"2021","journal-title":"Pharmacol Res."},{"key":"R12-20260108","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/psp4.12810","article-title":"Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles","volume":"11","author":"Labriffe","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R13-20260108","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11095-022-03252-8","article-title":"A machine learning approach to predict interdose vancomycin exposure","volume":"39","author":"Bououda","year":"2022","journal-title":"Pharm Res."},{"key":"R14-20260108","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3390\/pharmaceutics14051023","article-title":"Application of machine learning classification to improve the performance of vancomycin therapeutic drug monitoring","volume":"14","author":"Lee","year":"2022","journal-title":"Pharmaceutics"},{"key":"R16-20260108","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cpt.2148","article-title":"Real-world infliximab pharmacokinetic study informs an electronic health record-embedded dashboard to guide precision dosing in children with Crohn's disease","volume":"109","author":"Xiong","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"R18-20260108","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3390\/healthcare11121808","article-title":"Ensemble learning for disease prediction: a review","volume":"11","author":"Mahajan","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"R19-20260108","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm."},{"key":"R20-20260108","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/jimaging8110310","article-title":"A review of synthetic image data and its use in computer vision","volume":"8","author":"Man","year":"2022","journal-title":"J Imaging"},{"key":"R21-20260108","doi-asserted-by":"crossref","first-page":"105241","DOI":"10.1016\/j.ijmedinf.2023.105241","article-title":"Machine learning in medication prescription: a systematic review","volume":"180","author":"Iancu","year":"2023","journal-title":"Int J Med Inform."},{"key":"R22-20260108","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/cpt.2088","article-title":"Continuous learning in model-informed precision dosing: a case study in pediatric dosing of vancomycin","volume":"109","author":"Hughes","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"R23-20260108","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/psp4.12745","article-title":"A continued learning approach for model-informed precision dosing: updating models in clinical practice","volume":"11","author":"Maier","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R24-20260108","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0000000000001078","article-title":"Artificial intelligence and machine learning approaches to facilitate therapeutic drug management and model-informed precision dosing","volume":"45","author":"Poweleit","year":"2023","journal-title":"Ther Drug Monit."},{"key":"R25-20260108","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S2589-7500(20)30102-3","article-title":"Clinical applications of continual learning machine learning","volume":"2","author":"Lee","year":"2020","journal-title":"Lancet Digit Health"},{"key":"R26-20260108","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1016\/S2589-7500(21)00076-5","article-title":"Continual learning in medical devices: FDA's action plan and beyond","volume":"3","author":"Vokinger","year":"2021","journal-title":"Lancet Digit Health"},{"key":"R27-20260108","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/ibd\/izac237","article-title":"Model-informed precision dosing for biologics is now available at the bedside for patients with inflammatory Bowel disease","volume":"29","author":"Colman","year":"2023","journal-title":"Inflamm Bowel Dis."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:01:51Z","timestamp":1767848511000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001348","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"2025-03-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}